Natera Inc.

3 days ago · benzinga.com

On CNBC's “Halftime Report Final Trades,” Rob Sechan, founder and managing partner of NewEdge Capital Group, picked eBay Inc. (NASDAQ:EBAY).

4 days ago · zacks.com

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago · zacks.com

Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.

6 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera's technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications. Results from the phase III VOLGA trial in muscle-invasive bladder canc.

7 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera's genetic test for CKD. Among the key findings were data from a large, real-worl.

8 days ago · fool.com

Druckenmiller owns a large stake in Natera. The company is growing quickly by disrupting the healthcare testing market.

12 days ago · zacks.com

NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.

15 days ago · gurufocus.com

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology wi

18 days ago · fxempire.com

Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.

18 days ago · businesswire.com

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME's Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.TIME's Best Inventions list, published annually, highlights the technologies and breakthroughs making the world better, smarter, and more innovative. To compile this year's list, TIME solicited.